tabelecleucel

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 16/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Epstein-Barr Virus (EBV) Infections

Conditions

Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications

Trial Timeline

— → —

NCT ID

NCT02822495

About tabelecleucel

tabelecleucel is a pre-clinical stage product being developed by Atara Biotherapeutics for Epstein-Barr Virus (EBV) Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT02822495. Target conditions include Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02822495	Pre-clinical	Completed	—	—	Epstein-Barr Virus (EBV) Infections

Competing Products

5 competing products in Epstein-Barr Virus (EBV) Infections

See all competitors

Product	Company	Stage	Hype Score
mRNA-1189	Moderna	Phase 1	0
mRNA-1189	Moderna	Phase 2	0
mRNA-1195.1	Moderna	Phase 1	0
Nanatinostat in combination with valganciclovir	Viracta Therapeutics	Phase 2	17
Durvalumab + Epacadostat	AstraZeneca	Phase 2	27